Giredestrant reduces recurrence in HR-positive, HER2-negative breast cancer In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment. The finding points to a potential new treatment option for the most common subtype of breast cancer, which accounts for roughly 70% of all cases and is most often diagnosed at Stage 1, 2, or 3. Seeking commentary, including: How could these findings potentially improve future care?

These new findings on giredestrant matter a lot to us. If recurrence rates go down, my breast reconstruction patients get more peace of mind about their future. I've seen better cancer control give us the flexibility to focus on cosmetic details and what the patient actually wants. We just need to keep working closely with our oncology team so patients get the best cancer care and reconstruction possible.

The success of Giredestrant signifies a promising shift in the treatment of early-stage HR-positive, HER2-negative breast cancer patients, which is the most common subtype of breast cancer. These findings provide oncologists with a new potential front-line option that can be easily integrated into patient care and disease management, moving away from current drug therapies like Aromatase Inhibitors or Tamoxifen, especially for patients who have a higher risk of recurrence. With this, a greater number of patients now have increased rates of survival, have a better outlook on long-term disease free survival rates, and are more likely to adhere to their treatment plans and be proactive in their care. This also reduces the need for more intensive or sequential therapies down the line. Furthermore, the data that shows the reduced rates of cancer recurrence with Giredestrant can accelerate the movement towards personalized endocrine therapy and can allow for more targeted and aggressive initial treatment for patients who are HR-positive, HER-2 negative.